AU2010204459B2 — c-MET modulators and methods of use
Assigned to Exelixis Inc · Expires 2013-06-20 · 13y expired
What this patent protects
C.\NRPorb\DCC\AMW3) 7042_L DOC-2GA7/2010 The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed 5 cell death, migration and chemoinvasion. More specifically, t…
USPTO Abstract
C.\NRPorb\DCC\AMW3) 7042_L DOC-2GA7/2010 The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed 5 cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. 10 The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.